Progress in the treatment of vascular complications in type 2 diabetes by finerenone in combination with RAS inhibitors/SGLT-2i

In summary, combining finerenone with RAS inhibitors and SGLT-2i is a promising treatment strategy. However, the molecular mechanisms and interactions are not fully understood, necessitating more basic research and clinical trials to provide evidence. Combining finerenone with existing treatments may yield better clinical outcomes.